Avelumab
- Generic Name
- Avelumab
- Brand Names
- Bavencio
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1537032-82-8
- Unique Ingredient Identifier
- KXG2PJ551I
- Background
Avelumab is a human IgG1 lambda monoclonal antibody that binds programmed cell death ligand-1 (PD-L1) to block its interaction with its receptors found on T cells and antigen-presenting cells. Avelumab was first approved by the FDA on March 23, 2017. On September 18 and December 18 of the same year, it was also granted approval by EMA and Health Canada, res...
- Indication
Avelumab is indicated for the treatment of adults with metastatic Merkel cell carcinoma (MCC). In the US, it is also used in patients 12 years and older.
...
- Associated Conditions
- Advanced Renal Cell Carcinoma, Metastatic Urothelial Cancer, Locally advanced Urothelial Carcinoma, Metastatic Merkel Cell Carcinoma (MCC)
- Associated Therapies
- First Line Chemotherapy, Maintenance therapy
A Study of Avelumab in Penile Cancer Who Are Unfit for or Have Progressed After Platinum-Based Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2018-01-05
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 24
- Registration Number
- NCT03391479
- Locations
- 🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
OX40, Venetoclax, Avelumab, Glasdegib, Gemtuzumab Ozogamicin, and Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia
- First Posted Date
- 2018-01-04
- Last Posted Date
- 2023-09-05
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 50
- Registration Number
- NCT03390296
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Phase II Study of Avelumab in Patients With Advanced Hepatocellular Carcinoma After Prior Sorafenib Treatment
- First Posted Date
- 2018-01-03
- Last Posted Date
- 2021-03-17
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT03389126
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed
- Conditions
- Interventions
- Drug: Aldoxorubicin HClBiological: ETBX-011Biological: ETBX-021Biological: ETBX-051Biological: ETBX-061Biological: GI-4000Biological: GI-6207Biological: GI-6301Biological: haNK for infusionDrug: AvelumabDrug: bevacizumabDrug: CapecitabineDrug: CetuximabDrug: CisplatinDrug: CyclophosphamideDrug: FluorouracilDrug: LeucovorinDrug: nab-PaclitaxelDrug: NecitumumabProcedure: SBRTBiological: N-803
- First Posted Date
- 2017-12-29
- Last Posted Date
- 2024-08-05
- Lead Sponsor
- ImmunityBio, Inc.
- Target Recruit Count
- 4
- Registration Number
- NCT03387111
- Locations
- 🇺🇸
Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States
Survival Prolongation by Rationale Innovative Genomics
- Conditions
- Interventions
- First Posted Date
- 2017-12-29
- Last Posted Date
- 2023-12-18
- Lead Sponsor
- Worldwide Innovative Network Association
- Target Recruit Count
- 15
- Registration Number
- NCT03386929
- Locations
- 🇺🇸
Avera Cancer Center, Sioux Falls, South Dakota, United States
🇱🇺Centre Hospitalier Luxembourg, Luxembourg, Luxembourg
🇮🇱Chaim Sheba Medical Center, Ramat Gan, Israel
Avelumab Treatment in Patients With Neuroendocrine Carcinomas (NEC G3) Progressive After Chemotherapy
- First Posted Date
- 2017-11-24
- Last Posted Date
- 2022-02-25
- Lead Sponsor
- Johannes Gutenberg University Mainz
- Target Recruit Count
- 60
- Registration Number
- NCT03352934
- Locations
- 🇩🇪
Nationales Centrum für Tumorerkrankungen Universitätsklinikum Heidelberg, Heidelberg, Germany
🇩🇪Poliklinik für Innere Medizin I Universitätsklinikum Halle, Halle (Saale), Germany
🇩🇪Schwerpunkt Endokrinologie und Stoffwechselerkrankungen Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz, Germany
Avelumab With Laser Interstitial Therapy for Recurrent Glioblastoma
- Conditions
- Interventions
- First Posted Date
- 2017-11-14
- Last Posted Date
- 2022-01-04
- Lead Sponsor
- Icahn School of Medicine at Mount Sinai
- Target Recruit Count
- 13
- Registration Number
- NCT03341806
- Locations
- 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
Neoadjuvant AXITINIB and AVELUMAB for Patients With Localized Clear-cell RCC
- First Posted Date
- 2017-11-14
- Last Posted Date
- 2018-05-21
- Lead Sponsor
- The Netherlands Cancer Institute
- Target Recruit Count
- 40
- Registration Number
- NCT03341845
- Locations
- 🇳🇱
Antoni van Leeuwenhoek, Amsterdam, Netherlands
QUILT-3.060: NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy
- Conditions
- Interventions
- First Posted Date
- 2017-11-01
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- ImmunityBio, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT03329248
- Locations
- 🇺🇸
Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States
First-line Gemcitabine/Cisplatin +/- Avelumab in Locally Advanced or Metastatic Bladder Carcinoma
- First Posted Date
- 2017-10-27
- Last Posted Date
- 2022-05-03
- Lead Sponsor
- University Hospital, Bordeaux
- Target Recruit Count
- 65
- Registration Number
- NCT03324282
- Locations
- 🇫🇷
Hôpital Saint-Louis, AP-HP, Paris, France
🇫🇷Hôpital Européen Georges-Pompidou, AP-HP, Paris, France
🇫🇷CHU de Besançon, Besançon, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.